Beyonttra®▼ (acoramidis) for ATTR-CM (transthyretin amyloid cardiomyopathy): Acoramidis Indication and Approval
This page provides UK healthcare professionals with a consolidated overview of Beyonttra (acoramidis) in transthyretin amyloid cardiomyopathy (ATTR-CM), including its licensed indication, NICE positioning, and regulatory approval status in the UK. Use the links below to navigate directly to the relevant sections on this page.
What is acoramidis?
Beyonttra contains the active substance acoramidis (pronounced a-cor-am-i-dis), an orally administered medicine that works to stabilise transthyretin (TTR). TTR is a protein that can become unstable, misfold and form amyloid deposits in the body. These deposits can accumulate in the heart, leading to a serious condition known as transthyretin amyloidosis with cardiomyopathy (ATTR‑CM).
ATTR‑CM is a progressive disease, leading to
Heart failure
Reduced functional capacity
Increased mortality
Acoramidis is designed to help slow disease progression, and is used in adult patients with a confirmed diagnosis of wild‑type or variant ATTR‑CM. In the UK, Beyonttra is indicated for long‑term use as part of the ongoing management of ATTR‑CM in accordance with its licensed indication and national guidance.
What is acoramidis used for?
Acoramidis licensed indication for ATTR‑CM
Acoramidis is approved for the treatment of wild-type or variant transthyretin amyloidosis with cardiomyopathy (ATTR‑CM) in adult patients. The acoramidis indication includes use in patients with:
- Wild-type ATTR-CM, typically presenting later in life
- Variant (hereditary) ATTR-CM, associated with pathogenic TTR variants
Beyonttra approval and regulatory status in the UK
Acoramidis approval: In the UK, the National Institute for Health and Care Excellence (NICE) has published technology appraisal guidance TA1121, which recommends acoramidis as a treatment option for eligible adult patients with ATTR-CM, in line with its marketing authorisation and subject to commercial arrangements.
Acoramidis NICE guidance should be consulted for full details on patient eligibility, positioning within the treatment pathway, and commissioning considerations.
Bayer Beyonttra: Bayer oversees Beyonttra's commercial activity in both the UK and EU.
Abbreviation:
NICE, National Institute for Health and Care Excellence; SmPC, Summary of Product Characteristics.
PP-BEY-GB-0284 | August 2026